Gastric cancer is one of the prevalent cancer types in the Far East region. In order to discover new prognostic and diagnostic biomarkers for gastric cancer progression, we have used degenerated PCR primers designed to amplify all expressed protein tyrosine kinase molecules from human cancer tissues. In previous studies, we have shown the clinical significance of arg tyrosine kinases in a colorectal cancer progression model.
We further investigated the protein expression of arg tyrosine kinase by immunohistochemistry and analyzed the clinicopathological association with human cancers.
Specimens from 79 patients were examined and this demonstrated that the expression of arg kinase showed no statistically significant correlation with the patients' overall survival. However, higher levels of arg kinase immunoreactivity did show a statistically significant association with vessel invasion in gastric cancer tissues examined. This indicates a potential involvement of arg in gastric cancer invasion and progression.
"Our laboratory has been exploring the utilisation of PTK and protein tyrosine phosphatase genes as biomarkers in human gastric cancers (Refs 34, 35, 36). Various PTKs, the expression of which is elevated in human gastric cancers, have also been studied (Refs 37, 38, 39, 40). We demonstrated that two PTKs, tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE-1) and mitogen-activated protein kinase kinase 4 (MKK4), serve as new molecular biomarkers for gastric cancer prognosis. "
[Show abstract][Hide abstract] ABSTRACT: Carcinoma of the stomach is one of the most prevalent cancer types in the world. Although the incidence of gastric cancer is declining, the outcomes of gastric cancer patients remain dismal because of the lack of effective biomarkers to detect early gastric cancer. Modern biomedical research has explored many potential gastric cancer biomarker genes by utilising serum protein antigens, oncogenic genes or gene families through improving molecular biological technologies, such as microarray, RNA-Seq and the like. Recently, the small noncoding microRNAs (miRNAs) have been suggested to be critical regulators in the oncogenesis pathways and to serve as useful clinical biomarkers. This new class of biomarkers is emerging as a novel molecule for cancer diagnosis and prognosis, including gastric cancer. By translational suppression of target genes, miRNAs play a significant role in the gastric cancer cell physiology and tumour progression. There are potential implications of previously discovered gastric cancer molecular biomarkers and their expression modulations by respective miRNAs. Therefore, many miRNAs are found to play oncogenic roles or tumour-suppressing functions in human cancers. With the surprising stability of miRNAs in tissues, serum or other body fluids, miRNAs have emerged as a new type of cancer biomarker with immeasurable clinical potential.
Expert Reviews in Molecular Medicine 03/2014; 16(2):e1. DOI:10.1017/erm.2013.16 · 5.15 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Thymoma is one of the most common solid tumors in the mediastinum. As there is no typical cell line for human thymoma, the development and use of molecular-based therapy for thymoma will require detailed molecular genetic analysis of patients' tissues. The recent reports showed that the gain of chromosome 1q regions was frequent in thymoma. We investigated the use of oligonucleotide arrays to monitor in vivo gene expression levels at chromosome 1q regions in the early- (stage I or II) and late-stage (stage IVa) thymoma tissues from patients. These in vivo gene expression profiles were verified by real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) using LightCycler for 36 thymoma patients. Using both the methods, candidate genes were come up. These are Arg tyrosine kinase and death-associated protein 3 (DAP3), which are known as ionizing radiation resistance conferring proteins. The Arg/GAPDH mRNA level in stage IV thymoma (90.716 +/- 177.851) was significantly higher than in stage I thymoma (10.335 +/- 25.744, P = 0.0465). The DAP3/GAPDH mRNA level in stage IV thymoma (17.424 +/- 20.649) was significantly higher than in stage I thymoma (5.184 +/- 3.878, P = 0.0305). DAP3 expression was also correlated with the WHO classification. The combined use of oligonucleotide microarray and real-time RT-PCR analyses provided a candidate molecular marker surrounding the development and progression of thymoma correlated with chromosome 1q.
[Show abstract][Hide abstract] ABSTRACT: There are some evidences on involvement of ABL2 in a number of cancers, especially ABL2 overexpression was observed in Raji, a Burkitt's lymphoma (BL) cell line. Therefore ABL2 overexpression may be involved in pathogenesis of Burkitt's lymphoma. The aim of this study was to evaluate ABL2 significance in BL. For this purpose 20 formaldehyde fixed paraffin embedded blocks – 16BL and 4 normal lymph nodes – were used. Sections were prepared from the paraffin blocks and treat with primary and then secondary antibodies. Two proteins, ABL2 (the test protein) and GAPDH (a control house keeping protein) were studied, ABL2 was labeled green and GAPDH red. After capturing the pictures using a CCD camera, the intensity of green and red colures were measured and ratio between green/red, that demonstrate changes in ABL2 expression, were calculated. The expression of ABL2 protein in BL and normal lymph node was considerably different and BL had higher expression of ABL2 protein compared to normal lymph nodes. The mean ratio of ABL2/GAPDH in Bl and normal lymph node was 0.68 and 0.65, respectively. Like other malignancies, finding about gene expression patterns in BL seems to be helpful in future board therapeutic guidelines. Then specific inhibitors of ABL2 would be considered as new chemotherapy agents in BL treatment.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.